HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR – Free Report) in a research note released on Friday,Benzinga reports. The firm currently has a $37.00 price target on the stock.
Separately, Jefferies Financial Group assumed coverage on Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective for the company.
View Our Latest Analysis on Pharming Group
Pharming Group Trading Up 0.3 %
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $92.70 million during the quarter, compared to analysts’ expectations of $76.67 million. As a group, analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR – Free Report) by 16.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
- Five stocks we like better than Pharming Group
- Following Congress Stock Trades
- How to Build the Ultimate Everything ETF Portfolio
- Bank Stocks – Best Bank Stocks to Invest In
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.